Editas Medicine (EDIT) Profit After Tax Growth (3y) (2018 - 2025)
Editas Medicine (EDIT) Profit After Tax Growth (3y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 70.25% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 47.10% |
| 10 | Editas Medicine | 243.24 Mn | 96.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 23.33% |
| Jun 30, 2025 | 0.14% |
| Mar 31, 2025 | -14.63% |
| Dec 31, 2024 | -3.09% |
| Sep 30, 2024 | -16.72% |
| Jun 30, 2024 | -6.96% |
| Mar 31, 2024 | -2.98% |
| Dec 31, 2023 | 32.91% |
| Sep 30, 2023 | -97.96% |
| Jun 30, 2023 | -19.56% |
| Mar 31, 2023 | -9.14% |
| Dec 31, 2022 | -17.16% |
| Sep 30, 2022 | -19.15% |
| Jun 30, 2022 | -16.52% |
| Mar 31, 2022 | -19.98% |
| Dec 31, 2021 | -18.26% |
| Sep 30, 2021 | -36.88% |
| Jun 30, 2021 | -12.58% |
| Mar 31, 2021 | -22.40% |
| Dec 31, 2020 | -19.98% |